Background Malignant mesothelioma is a malignancy with a primary resistance to chemo-and radiotherapies for reasons which are still unclear. Multidrug resistance proteins might explain the observed resistance, but no studies have assessed their expression in mesothelioma
Introduction
Mesothelioma is a tumor derived from the serosal lining of the pleura and peritoneal cavities It is a tumor caused mainly by occupational exposure to asbestos fibers and its prognosis is dismal. However uncommon, mesothelioma represents an interesting tumor-model as it is primarily resistant to all treatment modalities. The resistance mechanisms remain unclear, yet free radical mediated pathogenesis may influence the expression of different enzymes that can contribute to drug resistance.
Resistance of tumor cells to chemotherapeutic drugs and to radiation is a common cause of failure in treating patients with cancer. Several types of chemoresistance have been described in human carcinoma cell lines in vitro [1] [2] [3] [4] . The most studied resistance mechanisms include the 170 kDa P-glycoprotein (P-gp) encoded by MDR1 gene [5] and the recently discovered multidrug resistance protein family (MRP) [6, 7] . These both belong to the ATP-binding cassette (ABC) family of transporters [8] . The classical form of multidrug resistance is due to P-gp, which is a plasmamembrane protein that transports chemotherapeutic drugs out of the cell, thus reducing the intracellular drug accumulation P-gp is known to transport agents such as anthracyclines, vincaalkaloids, taxol and epipodophylotoxins [1] .
The MRP family currently has seven members of which at least the first three correlate with increased chemoresistance [9] . Best characterised are the human MRP1 and MRP2. MRP1 is a 190 kDa glycoprotein which mediates the transport of many glutathione S-conjugates extra-and intracellularly [8, [10] [11] [12] . Preferred substrates are organic anions, e.g. drugs conjugated to glutathione, sulphate or glucuronate [9] . MRP2, previously known as canahcular multispecific organic anion transporter (cMOAT), was first found from the canalicular membrane of hepatocytes [9] . It is also involved in the transport of organic anions across the plasma membrane [13] and its expression is associated with cisplatin resistance [9, 14] . In many studies MRPmediated transport has been linked to the cellular glutathione level [2, 15, 16] Furthermore, glutathione synthesis by gamma-glutamylcysteine synthetase (yGCS) has been shown to correlate with MRP levels and chemoresistance [17] [18] [19] , correlation being better with MRP1 than MRP2 in human lung cancer cells [13] . The MRP family plays part in the oxidant defence of the tumor cells as many cytotoxic drugs produce toxic oxygen species [8, 20] .
Unselected lung cancer cell lines and lung tumors express undetectable or very low levels of MDR1 gene Therefore, it is suggested that drug resistance of this tumor may be due to other mechanisms such as MRP [5, [21] [22] [23] [24] [25] The majority of all histological subtypes of non-small-cell lung cancer, but not of small-cell lung cancer, have detectable levels of MRP when assessed with immunohistochemistry, [24, 26, 27] . In normal lung tissue MRP1 has been detected in bronchial epithelium and hyperplastic pneumocyte II cells [24, 28] . Surprisingly, however, the staining may be even more intense in the areas of normal lung than in the malignant cells [22] . Therefore, many aspects of the role of MRP1 have remained unclear, especially in lung cancer The expression of MRP2 in lung cancer has not been thoroughly studied. MRP2 mRNA seems to be present in cultured cell lines as well as in samples of patient tissues with no difference between NSCLC and SCLC However, the possible correlation between MRP2 and drug resistance is also unsolved [7] .
Mesothehoma provides an interesting model for the investigation of drug resistance. So far no treatment has had significant effects on the survival of these patients. There is one cell line study on MDR1 and MRP in mesothehoma and this study investigated MDR1-and MRPI-mRNA only in cultured cells [29] . In this study MDR1 gene was not overexpressed in any of the five mesothehoma cell lines investigated, and MRP was coordinately over-expressed in two cell lines with yGCS and correlated with doxorubicin resistance in mesothelioma cell lines in vitro. On the other hand, another study suggested that the resistance of the mesothehoma cell line is due to P-gp [30] . In this particular study, however, the parental mesothehoma cell lines showed only weakly positive immunostaining (1%) with the P-gp antibody.
We wanted to investigate P-gp protein encoded by the MDRl-gene and MRP expressions in the biopsies of mesothehoma in vivo. Healthy mesothelium and mesothehoma tissues of 36 patients were investigated for P-gp, MRP1 and MRP2 using immunohistochemistry. We also investigated the association of P-gp, MRP1 and MRP2 immunostaining with patient survival.
Patients and methods

Histological material
Thirty-six malignant mesothehomas were retrieved from the files of the Department of Pathology. Oulu University Hospital, between 1976-1999 Additionally six samples of non-neoplastic pleural tissue were included All the material had been fixed in 10% buffered formalin and embedded in paraffin Malignant mesothehomas were subclassified into epithelial, sarcomatoid and biphasic subtypes according to the criteria given by AFIP [31] There were six women and 30 men in the study The mean age of the patients was 64 2 ± 10 3 years (min 33, max 79) The patients did not receive any systematic chemotherapy prior or after surgical therapy Occasional radiation treatment for pleural pain and occasional non-systemic chemotherapy was given to some patients
Immunohistochemical stainings for MDR, MRPI and MRP2
A mouse monoclonal IgGl antibody to human P-gp (JSB1, Alexis Biochemicals), to the carboxyterminal part of MRPI (MRPm6, Alexis Biochemicals) and to MRP2 (Alexis Biochemicals) were used in the immunohistochemical studies on tumor samples The immunostainmgs with the antibodies were performed as follows Before application of the primary antibodies, the sections were heated in a microwave oven in 10 mM citnc acid monohydrate, pH 6 0, for 10 minutes. The dilutions for the primary antibody for P-gp was 1 20, for MRPI 1 50 and for MRP2 1 50 The immunostaining was performed using the Histostain-Plus Bulk Kit (Zymed Laboratories Inc, South San Francisco) and the chromogen used was AEC (Zymed Laboratories Inc, South San Francisco) Negative control stainings were carried out by substituting non-immune mouse or rat serum for the primary antibodies A positive control consisted of samples from normal liver and liver tumors [32] The intensity of the immunostainings with all the antibodies was evaluated by dividing the staining reaction in four groups 1 = weak staining intensity, 2 = moderate staining intensity, = moderate immunostaining, scores 3-4, +++ = strong immunostaining, scores 5-8 Two authors evaluated the immunostaining separately, and the correlation coefficient was established according to Cohen's kappa statistics as described [33] There was a good association between the evaluation by the two investigators (Kappa coefficient = 0 57, P = 0 00106, Fisher's exact test)
Immunohistochemistry for Ki67
Tumor cell proliferation was studied with a monoclonal mouse anlihuman Ki-67 antibody (Zymed, San Francisco, California) Five um thick sections were cut from representative tumor blocks The sections were first deparaffinized in xylcne and rehydrated in descending ethanol series In order to enhance the immunoreactivity, the sections were incubated in 10 mM citrate buffer (pH 6 0) and boiled for 2 min at 850 W, followed by 8 min in 350 W Endogenous peroxidase activity was eliminated by incubation in 0.1% hydrogen peroxide in absolute methanol for 10 minutes The concentration of the primary anti-Ki67 antibody was 1 50 For anti-Ki-67 the avidin-biotin-peroxidase complex method was used, the color was developed using 3,3'-diaminobenzidine The sections were lightly counterstained with hematoxylin and mounted with Eukitt (Kindler, Freiburg, Germany) Replacement of the primary antibodies with phosphate-buffered saline (PBS) at pH 7 2 was used as a negative control The percentage of Ki-67-positive cells was assessed from 10 high power fields (HPFs) in each tumor section
3'-end labelling of DNA in apoptotic cells
In order to detect apoptotic cells, in situ labelling of the 3'-ends of the DNA fragments generated by apoptosis-associated endonucleases was performed using the ApopTag in situ apoptosis detection kit (Oncor, Gaithersburg, Maryland) Cells were defined as apoptotic if the whole nuclear area of the cell labelled positively Apoptotic bodies were defined as small positively-labelled globular bodies in the cytoplasm of the tumor cells which could be found either singly or in groups To estimate the apoptotic index (the percentage of apoptotic events in a given area), apoptotic cells and bodies were counted in 10 HPFs and this figure was divided by the number of tumor cells in the same HPFs
Statistical analysis
SPSS for Windows (Chicago, Illinois) was used for statistical analysis The significance of the associations was determined using Fisher's exact probability test, correlation analysis and two-tailed /-test The survival analysis was performed by the Kaplan-Meier curve and the significance of associations was tested by the log-rank, Breslow and Tarone-Ware tests. Probability values P < 0 05 were considered statistically significant
Results
The results of this investigation are shown in Table 1 . The reactivity of P-gp was mainly localized to plasma membrane. Of the malignant mesotheliomas, 22 of 36 (61%) cases showed positive staining, 13 cases showed strong, four moderate, and five weak staining ( Figure  1A ). Epithelial and biphasic malignant mesotheliomas revealed strong staining for P-gp significantly more often than sarcomatoid ones (P = 0 031). No positive staining was observed in non-neoplastic pleural mesothelial cells ( Figure IB) .
Positive immunoreactivity for MRP1 was seen in 21 of 36 (58%) cases, the staining was both membranebound and cytoplasmic ( Figure 1C) . Strong, moderate and weak reactivity for MRP1 was seen in seven cases, respectively. There was no significant association between MRP1 and P-gp staining (P -0 11). MRP1 immunoreactivity was weaker in sarcomatoid than epithelial or biphasic mesotheliomas (P = 0.034). No lmmunostainmg was seen in samples obtained from non-neoplastic mesothelium ( Figure ID) .
In addition to membrane-bound immunoreactivity, MRP2 antibody detected non-specific nuclear lmmunostaining but only membrane-bound staining was considered significant. Twelve of thirty-six (33%) cases showed positive reactivity ( Figure IE) . The staining was usually weak, and no cases with moderate or strong staining could be detected. There was a significant association between MRP2 and moderate or strong P-gp staining (P = 0.021), but no association between MRP2 and MRP1 reactivity (P = 0.41) There was a significant association between histological type of mesothehoma and MRP2 sarcomatoid mesotheliomas showing negative staining significantly more often than epithelial and biphasic ones (P = 0.024). No membrane-bound MRP2 positivity was observed in non-neoplastic mesothelium ( Figure IF) . There was no significant association with patient survival and expression of any of the multidrug proteins studied {P -0.135, p=0.09 and P = 0.88 for P-gp, MRP2 and MRP1, respectively). When the material without sarcomatoid mesotheliomas was studied, the results remained the same (P -0.12, P = 0.13 and P -0.72, respectively). The mean proliferation index in malignant mesotheliomas was 6.3% ± 9.2% and the mean apoptotic index was 0.58% ± 0 68%. There was no association between MDR, MRPI or MRP2 expression and tumor proliferation or apoptosis.
Discussion
The immunohistochemical expression of multidrug resistance proteins P-gp, MRPI, and MRP2 was investigated in 36 cases of malignant mesotheliomas. In contrast to lung cancer, which is usually negative for P-gp, expression of P-gp was positive in 61% of the cases of mesothehoma P-gp positivity has previously been shown in several types of other tumors, such as carcinomas of breast, kidney, colon and liver [32, [34] [35] [36] [37] , and its expression has been shown to be associated with a shorter survival in these tumors [32, 34, 36, 37] . In contrast with other tumors, loss of P-gp expression has even been associated with a poorer prognosis in breast carcinomas [38] . Regardless of its expression in malignant mesothelioma, which is comparable to the expression of the tumors mentioned above, we could not find any significant association with patient survival and P-gp expression. This suggests that P-gp-associated mechanisms do not play a decisive part in malignant mesothelioma.
To further explore the reason for the aggressive behaviour of malignant mesothelioma, the biopsies were stained with antibodies to multidrug resistance proteins MRPI and MRP2 MRPI expression was found in 60% of the cases. This is in line with the frequencies found in different types of tumors such as colon or gastric carcinomas, for instance, where MRPI expression is found in 70% and 55% of the cases, respectively [39] [40] [41] . In non-small-cell lung carcinomas the reported incidence of MRP1 positivity is variable, some authors reporting low [5] and some higher expression [26, 27] Similarly, in small-cell carcinomas, the reported incidence varies from 0% to 31% [27, 42] . As with P-gp, the expression of MRP1 has been associated with poor prognosis in other tumors, such as non-small-cell lung carcinomas [43] , ovarian [44] and endometnal carcinomas [45] . However, such association has not been found in types of tumors such as carcinomas of the head and neck [46] , colon [47] or breast [48] . We found positive MRP2 reactivity in 33% of the cases. To our knowledge relatively little is known about the role of MRP2 in malignant tumors and no previous studies have been conducted on MRP2 in mesothelioma. It has to be noted that no chemotherapeutic agents have had any effect on the survival of mesothelioma patients to date In this study, four of the patients had received chemo-or radiotherapy before the biopsy, and no systematic treatment protocols were offered to anyone after the diagnosis. Some patients had obtained local palliative radiotherapy for tumor-related thoracic pain or 1-2 courses of various chemotherapies which were not standardized. Therefore, the role of MRP on the chemoresistance of mesothelioma remains to be evaluated.
In malignant mesothehomas, stronger expression of P-gp and MRP2 was found in epithelial and biphasic mesotheliomas. Furthermore, only one sarcomatoid mesothelioma showed positive MRP1 lmmunoreactivity. In some other types of tumors MRP1 expression has been associated with tumor cell differentiation In non-small-cell lung carcinomas, stronger MRP1 expression was found in well-differentiated squamous cell carcinomas [26] . Analogously, Sugawara et al. reported higher incidence of MRP1 expression in well-differentiated adenocarcinomas of the lung [27] . Contrary to lung carcinomas, in thyroid carcinomas higher MRP1 expression was found in anaplastic carcinomas where 52% of such tumors showed positive expression [49] . Thus MRP1 expression may be a trait of tumor differentiation, as seems to be the case in malignant mesothelioma.
There was a significant association between the expression of P-gp and MRP2 in malignant mesothelioma and there was also a tendency for a similar expression for P-gp and MRP1 (P = 0.11) (see Table 1 ) P-gp and MRP1, however, belong to separate groups of multidrug resistance proteins and separate genes encode them. Usually drug resistance unassociated with P-gp has been ascribed to MRP proteins. It has, however, also been shown that MDR1 and MRP genes may be expressed in the same cell lines; for instance, expression of both genes was detected in H69 small-cell lung cancer cell line after exposure to etoposide [50] . Our results showed concomitant expression of P-gp, MRP1 and MRP2 in six cases (see Table 1 ) Curiously, in survival analysis, such cases did not have a poorer prognosis than other cases (P -0 90).
Our results thus show that regardless of the expression of P-gp, MRP1 and MRP2 in malignant mesothelioma, their expression is not associated with prognosis. Consequently there have to be other mechanisms which would account for the poorer prognosis of malignant mesothelioma. In fact, at least seven different MRP proteins are found [9] . Some of these proteins, which were not studied here, may play a more decisive role in the progression of malignant mesothelioma. Alternatively some other mechanisms, such as resistance of the tumor cells themselves to apoptosis, might lie behind their resistance. Malignant mesotheliomas have been shown to express several of the proteins of the bcl-2 family [51] . However, expression of bcl-2 in mesotheliomas is low [51] . Mesothelioma cell lines show variable sensitivity to epirubicin-induced apoptosis [52] and the extent of apoptosis in this tumor is similar to that found in many other tumors [51] . Thus, resistance to apoptosis cannot fully account for the chemoresistance found in malignant mesothelioma, either.
Yet another possible mechanism of resistance in mesothelioma is drug detoxification by GST or other GSH-related mechanisms, including antioxidant defence of malignant cells [53, 54] . These mechanisms may play a potential role in the drug resistance of malignant mesothelioma, since in our previous studies the most resistant mesothelioma cell line contained not only highest glutathione content but also elevated levels of GST and glutathione peroxidase [55] It is also possible that these glutathione-associated mechanisms may correlate with the expression of MRP and that co-ordinated expression of several of these pathways acts simultaneously in malignant mesothelioma.
In conclusion, this is the first study on the expression of multidrug resistance proteins in malignant mesothelioma. The results show considerable expression of P-gp, MRP1 and MRP2 Regardless of the high primary chemoresistance of malignant mesothelioma and the widespread expression of the multidrug-resistant proteins P-gp, MRP1 and MRP2 in them no association with tumor prognosis and their expression could be found. One reason for this fact may be that other MRP proteins might play a more important part in chemoresistance of malignant mesothelioma. Alternatively, some other biological factors, such as resistance of the tumor cells to apoptosis or cell death caused by the chemotoxic agents might contribute to this phenomenon. Overall, however, the chemoresistance in malignant mesothelioma still remains obscure.
